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Summary 
Exon-shuffled constructs between mouse (IAB  b) and human (DR33) class II B chains were made 
to study the interaction sites between CD4 and major histocompatibility complex (MHC) class 
II molecules, and to determine whether a species barrier is involved. The overall structure and 
the peptide binding groove appeared to be unaffected by the exon shuffling procedure as determined 
by monodonal antibody and peptide binding assays, respectively. While purified CD4 + BALB/c 
T  cells responded strongly in a mixed leukocyte reaction to transfectants expressing the whole 
IA molecule, the response to IA molecules containing a DI~2 domain was substantially reduced. 
In addition, the presence of an IA32 domain in DR failed to restore the weak xenoreactivity 
to the whole DR molecule. Similar observations were made with murine HEbspecific, IAolkB  b- 
restricted T cell hybridomas which responded significantly stronger to the whole compared with 
the exon-shuffled IA molecules. The involvement of CD4 in these differential responses was 
confirmed by the observation that CD4 loss variants responded to both molecules comparably, 
and transfection of CD4 into these cells restored the parental phenotype. In contrast, CD4 loss 
variants transfected with human CD4 responded equally to both the whole and the exon-shuffled 
molecules. Taken together, these data imply the existence of a partial species barrier, and suggest 
that CD4 interacts with the 82 domain of MHC class II molecules, probably in addition to 
other contact sites. Models for the interaction of CD4 with MHC class II molecules are presented. 
T 
he interaction between CD4 and MHC class II mole- 
cules is known to be an important event in both T cell 
ontogeny (1) and peripheral activation of helper and cyto- 
toxic CD4 §  T  cells  (2-4).  Several studies have suggested 
that CD4 binds to a nonpolymorphic region of class II mol- 
ecules thereby increasing the affinity of the interaction be- 
tween an antigen-presenting cell and a T  cell (5-8). Direct 
evidence for a physical interaction between CD4 and class 
II molecules was first obtained by Doyle and Strominger (9) 
using an adhesion assay between class II + B cells and a high 
CD4-expressing CV1  transfectant. 
CD4 consists of four external Ig-like domains (D1-4), a 
transmembrane region, and a cytoplasmic tail. The two do- 
mains furthest from the cell surface (D1 and 2) have been 
shown to contain residues involved in binding to class II mol- 
ecules (10-12).  In contrast, very little is known about the 
interaction site on MHC class II molecules. Although there 
are some speculations that there may be interaction sites in 
the o~1 (13) and 31 (14,  15) domains, no direct conclusive 
evidence has been provided. 
Whether a species barrier exists in the interaction between 
CD4 and class II remains controversial. While Lamarre et 
al.  (11) have suggested that murine CD4 does not interact 
with human class II HLA-DP molecules, von Hoegen et al. 
(16) have shown that murine CD4 loss variants, transfected 
with either human or mouse CD4,  are functionally com- 
parable.  However, evidence for the existence of a species bar- 
rier has also come from studies with human MHC class II 
transgenic mice. Several studies have shown that while single 
DRc~ (17) and single DQ3 (13) transgenic mice function nor- 
mally in terms of their ability to delete TCR V311 + cells, 
double DQod3 transgenics fail to do so (18). Our own ex- 
periments and data from other laboratories (17) have sug- 
gested that DRc~ transgenic mice, that express DRo~ on the 
surface of class II + cells in association with IE3  b, are com- 
pletely comparable to IE + mice in their ability to positively 
select  TCR  V~6,  negatively select  V311,  and generate a 
specific, DRo~IE3b-restricted response. 
On the basis  of these observations, it seemed reasonable 
to suggest that such a species barrier may exist between CD4 
and the human class II B chain. To determine whether such 
a barrier does exist and attempt to map possible interaction 
sites on class II molecules for CD4, two exon-shuffled con- 
structs were made. The first encoding the 31  domain of 
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of DR33  (Aoe/A31:DKB2),  and  the second encoding the 
converse (DRoe/DRBl:A32).  These constructs were trans- 
fected, together with the appropriate oe chain genes, into two 
different APC, and analyzed using two different functional 
systems. 
Materials  and Methods 
Plasmids and Constructs.  Two exon-shufl]ed constructs were pro- 
duced for these studies. The first, pD10.4, encodes the/$1 domain 
of IA/$  b and the B2, transmembrane, and cytoplasmic domains of 
DR3B (see Fig. 1 a). The second, pD12.2, is the converse encoding 
the 151 domain of DR3/~ and the ~2,  transmembrane and cyto- 
plasmic domains of IA/~  b. The cosmid Cos4.1  containing the en- 
tire DR3/~ gene (generously provided by Bernard Mach, Univer- 
sity of Geneva, Geneva, Switzerland) and the entire IA/$  b gene in 
pBR322 were used to make the constructs. Production of a detailed 
restriction map of the DR3/$ gene revealed a unique EcoRV site 
within the second intron, and appropriate restriction sites within 
the IA/$  b gene were deduced from the published sequence.  It is 
important to note that nonhomologous class II genes were used 
to produce the exon-shuttted constructs. This was due to the avail- 
ability of the IAB  b and DR3/$ genes and information concerning 
appropriate cleavage sites. To our knowledge, no study has yet shown 
that the c~2 and 32 domains play a role in class II pairing,  pD10.4 
was produced by ligating a 5.7-kb PvulI fragment containing the 
promoter and first two exons of the IA/$  b gene, and an EcoRI/ 
PvulI fragment of pBR322, with a 8-kb EcoRV fragment con- 
taining exons  3-6 of the DR3/$ gene (see Fig.  1). 
pD12.2 was produced in four stages. First,  a 2.7-kb Dral frag- 
ment containing exons 3-6 of the IA/$  b gene was subcloned into 
the Sinai site of pUC19 (pDS.1).  To obtain the entire 3' region 
of the gene, a 2.4-kb BamHI fragment from the IA3  b gene was 
subcloned into pD5.1 cut with BamHI (pD6.6). In a separate sub- 
cloning event, a 15.5-kb SalI/EcoRV fragment containing the pro- 
moter and first two exons of the DP,3/$ gene was cloned into a 
SalI/SmaI cut pSP72 plasmid vector (Promega Corp., Madison, WI) 
to produce pdll.5. Finally, a 3.8-kb KpnI/SphI blunted fragment 
containing the entire insert from pD6.6 was cloned into the EcoRV 
site in pDll.5  (pD12.2). 
CD4 expression vectors were produced by inserting either mouse 
(kindly provided by Jane Parnes, Stanford University, Palo Alto, 
CA) or human ([19]; pSPG-T4) CD4 eDNA into pH3Apr-lneo 
([20]; kindly provided by Richard Kedes, Stanford University, Palo 
Alto, CA and Robert Lechler, Royal Postgraduate Medical School, 
London, England) that contain a human/$-actin promoter and a 
neomycin resistance  gene for selection. 
Peptide Production and Purification.  The HEL  peptide  46-61 
(NTDGSTDYGILQINSR: single letter amino acid code) was pro- 
duced by solid phase peptide synthesis  using a 430A synthesizer 
(Applied Biosystems Inc., Foster City, CA), essentially as described 
(21, 22). Biotinylated peptides were produced by biotinylating the 
NHrterminal  deprotected peptide before cleavage  using  a  10- 
molar excess of NHS-I.C-biotin II (Pierce Chemical Co., Rock- 
ford, IL). Crude peptides were extensively purified to homogeneity 
by reverse phase HPLC and the correct molecular weight verified 
by FAB mass spectroscopy. 
Monoclonal Antibodies.  The following antibodies were used to 
evaluate the conformational integrity of the exon-shuffled  mole- 
cules (all mouse mAbs unless stated):  Hl16-32 (23) and Hl18-48 
(23) recognize IAc~k; 17/227 (23), 25-9-17 (24), B17-123 (23) and 
B17-263 (23) recognize IA/$ba; K25-8.7 (25) recognizes IA/$  kb and 
P7/7 (rat mAb [26]) binds most IA alleles. All these mAbs have 
been shown to recognize conformational epitopes (27 and G. J. 
H~mmerling, unpublished data), except P7/7, which has not been 
tested. Other antibodies used in this paper were: L243-biotin recog- 
nizes DRot (28); GK1.5 recognizes mCD4 (rat mAb [29]); HP2.6 
recognizes hCD4 (30); 53-6.7 (rat mAb, 31), and 19/178 (32) recog- 
nize mCD8. 
Flow Cytometry and Peptide Binding Assay.  Cells were prepared 
for flow cytometric analysis  by staining with the relevant biotinylated 
or unconjugated antibody at saturating concentrations for 30 rain 
on ice in staining buffer (PBS containing 0.05%  NaN3  and 5% 
FCS). A20.J cells were also stained in the presence of 5% normal 
rabbit serum to block Fc receptor binding. Cells were washed twice 
and then stained  with either streptavidin-PE,  rabbit anti-mouse 
3" chain-PE or rabbit anti-rat-PE (Southern Biotechnology Assoc- 
iates,  Birmingham,  AL),  as described  above.  Finally,  cells were 
washed twice and resuspended in staining buffer containing 0.5 
#g/ml propidium iodide to facilitate the gating out of dead cells 
during flow cytometric analysis (FACScan~; Becton Dickinson & 
Co., Mountain View, CA). 
For the peptide binding assay, cells were incubated in the pres- 
ence of HEL 46-61 biotin at half-log10 dilutions from 102 to 10- 3 
#M at 37~  for 4 h. Cells were subsequently washed and stained 
with streptavidin-PE as described above. 
Transfection  Procedures.  Two transfection procedures were used. 
Calcium phosphate precipitation for Ltk-  L cells and electropo- 
ration for the A20.J B cells and the CD4 loss variant T cell hy- 
bridoma A167.N (Vignali, D., J. Moreno, D. Schiller, and G. H~m- 
merling,  manascript  submitted  for  publication)  as  previously 
described.  A20.J cells were transfected with either the IA& gene 
plus  IA/$  b or  ABI:DRB2,  or  the  DKot  gene  plus  DRB  or 
DR31:A/$2. 
Individual clones derived from either transfection method were 
obtained by staining with the relevant antibody and sorting at one 
cell/well into 96-well microtitre plates using a Coulter Autoclone 
system linked to an Epics V cell sorter (Coulter Corp., Hialeah, 
FL). Clones were routinely tested for homogeneous levels of MHC 
class II expression by flow cytometric analysis using a FACScan  ~ 
(Becton Dickinson & Co.). All T  cell hybridomas were further 
selected and routinely tested for their comparable expression of  TCR, 
CD3, CD2, and LFA-1, and comparable responses to immobilized 
anti-TCR and -CD3. Briefly, flat-bottomed 96-well microtiter plates 
were coated with  purified  anti-TCK  (H57.157)  or  anti-CD3e 
(500.A2) in PBS overnight at 37~  After extensive washing, T 
cell variants  were added at 5  x  104 in 200 #1. Supernatants (100 
#1) were removed after 24 h for estimation oflb2 secretion by cul- 
turing with the Ib2-dependent T cell line CTLL-2 (104; 100 #1). 
After 20 h, cells were pulsed for 8 h with 1 #Ci [3H]thymidine 
before liquid scintillation counting. SE was,  on average, <5%. 
MLR and Adhesion Assay.  CD4 § T  cells were purified from 
BALB/c spleens using a negative selection panning procedure as 
previously described (33).  MHC  class II + and CD8 + were re- 
moved using  the following mAbs;  P7/7  (IA),  25-9-17  (IA/$d), 
17/227 (IA/$d), 53-6.7  (CD8), and 19/178 (CD8). CD4 § T cells 
were assayed for purity and routinely found to be <1% IA +  , <1% 
CD8 § and >93%  CD4 +. 
A primary MLR was performed by culturing purified CD4 § 
T  cells  (5  x  10s; 100 #1) as responders with either syngeneic 
BALB/c or allogeneic C57B1/6 irradiated splenocytes (3,000 rads; 
2.5  x  10s; 100 #1), or irradiated A20.J (BALB/c origin) transfec- 
tants (10,000 tad; 2  x  104; 100 #1) as stimulators. After 3 d, 100 
#1 supernatant was removed for estimation of IL-2 using CTLL 
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ated visually  after 3 d before removal  of the supematant. Wells were 
scored as follows: (-) no significant clustering (<5 cells/cluster), 
(+) low clustering (5-50 cells/cluster), (+ +) moderate clustering 
(50-100 cells/cluster), (+ + +) extensive clustering (>100 cells/ 
cluster). 
Murine T Cell Hybridoma Experiments.  The hybridomas A167, 
A167.N, and A481, and the antigen presentation procedure have 
been described elsewhere (34, 35; Vignali, D., et al., manuscript 
submitted for publication). T cell variants were continually moni- 
tored for cell surface expression of important markers, responsive- 
ness to immobilized anti-TCR, and screened for mycoplasma to 
maximize reproducibility.  In addition, hybridomas  were passed fre- 
quently and kept in culture for no more than 4-6 wk, thereby lim- 
iting phenotypic change. T cell hybridomas (5  x  104; 100 ml) 
were cultured with 2.5  x  104 (100/zl) A20 transfectant and var- 
ious molar concentrations of either HEL (Sigma Chemical Co., 
St. Louis, MO) or the synthetic peptide 46-61. After 24 h, IL-2 
secretion was determined as described above. 
Results and Discussion 
To study  the interaction between  CD4 and MHC class 
II molecules, two exon-shu~ed constructs were made. One 
encoded the ~1 domain of IA  b and the ~2, transmembrane, 
and cytoplasmic domains of the nonhomologous human class 
II molecule, DR3, and the converse encoded the B1 domain 
of DR3 and the/~2, transmembrane, and cytoplasmic do- 
mains of IA  b (Fig.  1 A).  These constructs and the native 
genes were subsequently transfected, together with their ap- 
propriate o~ chains (IA~  k or DRc~)  into L cell fibroblasts 
(MHC class II negative) and A20.J B ceils (IA  a, IEa). The 
hybrid glycoproteins are referred to here as AodA~I:DR~2 
and DRcffDR~I:Afl2, respectively. Positive clones were iso- 
lated by FACS  |  with mAbs specific for the transfected gene 
products. The four heterodimer combinations together with 
the nomenclature used here are depicted in Fig.  1 B. 
The first question to answer was whether the exon-shuff~ng 
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Figure  1.  (.4)  Plasmid maps of IA/ 
IA:DR (pD10.4) and DR/DR:IA (pD12.2). 
See Materials and Methods for construc- 
tion protocol. (B) Diagrammatic  represen- 
tation of the structure of the MHC class 
II molecules used in this study and their 
nomenclature. AcffAB  represents IA,~k~; 
Ao~/A/~I:DR~2  represents an IAo~  k chain, 
and an ~on-shufl]ed  B chain  containing  an 
IABI~ domain and a DIC3B2, TM, and 
CY domain;  DRodDI~I:AI~2 represents 
a DR~ chain, and an e:~on-shuf~ed  ~ chain 
containing  a DR3~I domain  and an IA~2  b, 
TM, and CY domain; and DRoe/DR~ 
represents DR3~/~ The position of the 
od, c~2, ~1, B2, TM, and CY domains  are 
indicated. procedure had altered the conformation of these molecules. 
This was assessed by using both antibody and peptide binding 
assays. The ability of  eight anti-IA mAbs to recognize Ao~/A/~ 
and Aot/At31:DR[32, and  14  anti-DR  mAb  to  recognize 
DRc~/DRB  and DRot/DR/31:A/~2  was determined using 
flow cytometry (data not shown). The degree of binding of 
all mAbs between the exon-shuffled and native molecules was 
indistinguishable, demonstrating that the epitopes recognized 
by these mAbs were not destroyed or grossly altered. 
The  structural  integrity of the  exon-shuffled Aot/A/~l: 
DRy2 molecules was further assessed using a direct peptide 
binding assay. A20 transfected and untransfected cells were 
labeled with various concentrations of  biotinylated HEL 46-61 
followed by a streptavidin-PE  conjugate and subsequently ana- 
lyzed by flow cytometry (Fig.  2).  Staining of two Ac~/A8 
and AcffABI:DRB2 transfectants with  anti-IA mAb con- 
firmed that comparable levels of class II were present on the 
cell surface amongst  the different clones.  Only  low  level 
binding of the biotinylated peptide was observed to the IA  a 
and IE  d molecules on untransfected A20.J cells, and peptide 
bound to Ac~/AB (IAotk~  b) heterodimers in a high affanity, 
dose-dependent manner with detectable fluorescence down 
to  1 nM peptide. Similar results were obtained with L cell 
transfectants (data not shown). Taken together, these data 
clearly show that the peptide and antibody binding charac- 
teristics of all the AodA/~ and Ac~/ABI:DRB2 clones tested 
were indistinguishable,  suggesting that the exon shuffling 
procedure did not alter the ability of these molecules to bind 
immunogenic peptides. However, we cannot rule out the re- 
mote possibility that the peptide still binds to the same quan- 
titative extent, but in a conformation that reduces effective 
T  cell recognition. 
To assess the functional consequences of the exon shuffling 
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Figure 2.  The peptide binding groove of class II was not affected by 
the  exon  shuffling  procedure.  Two  different  Aot/AB (IAoek/3  b)  and 
Aot/A~I:DI~2 A20.J ttansfectants  together with untransfected  A20.J 
(IA~//3  a) cells were incubated with biotinylated HEL 46-61,  Hl16.32 
(IA/3k), and 25.9.17  (IA/~d), followed by streptavidin-PE.  Stained cells 
were analyzed by flow cytometry. Data presented are representative of four 
experiments, and are expressed as log10 mean fluorescence of individual 
samples. 
Figure 3.  Loss  of reactivity in a primary MLR. to MHC class II mole- 
cules containing a foreign B2 domain. CD4 + BALB/c spleen cells were 
used as responders against the following stimulators: BALB/c splenocytes 
(syngeneic), B6 splenocytes  (allogeneic), untransfected A20.J B cells (BALB/c 
origin),  and  the  Ao~/A/3,  A~x/A/31:DRB2,  DRo~/DR/31:AB2,  and 
DRu/DR/3 A20J transfectants. Supernatants were analyzed for Ib2 using 
a CTLL assay. Adhesion was determined visually. Wells were scored as 
follows: (-) no significant clustering was observed (<5 cells/cluster);  (+) 
low clustering (5-50 cells/cluster);  (+ +)  moderate clustering (50-100 
cells/cluster);  (+++)  extensive  clustering  (>100  cells/cluster).  Data 
presented are representative  of five experiments and are expressed as the 
mean of two transfectants analyzed in triplicate. Standard deviations were 
typically below 10%  of the total. 
isted in this interaction, two different antigen presentation 
systems  were used.  First,  a  primary MLR  using  murine 
CD4 §  T  cells as responders against the A20 transfectants, 
and second, a classical antigen presentation system using mu- 
rine HEbspecific,  IAo~k~b-restricted T  cell hybridomas. 
Purified CD4 + BALB/c splenocytes were used as respon- 
ders in a primary MLR against all four transfectants. A20.J 
cells  express IA  a and IE  d and are of BALB/c origin,  thus 
/ 
LII  A167  ￿9  A481  ~ 300 
~250  .'" 
g  = 
~200  .;  .  .r 
150 




50  r "~ 
-i  L  i  ~  , 
HEL  46-61  (~M). 
0  2 
10  10  10 
Figure 4.  Ability of IAcxk/3b-restricted  T  cell hybridomas to respond 
to HEL peptide 46-61 by AodA/3 or Acx/A31:DR,82  transfected  A20.J 
cells. Two hybridomas were analyzed, A167 and A481 and response deter- 
mined by Ib2 release. Data presented are representative of five experiments 
and are expressed as the mean of two transfectants  analyzed in triplicate. 
Data presented are representative  of seven experiments and are expressed 
as the mean of triplets. Standard deviations were typically below 10% of 
the total. 
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constitutively expressed class II, In addition, it has been demon- 
strated that  the IAc~k/3  b chains do not pair with  the IA  d 
chains (36).  However, it is probable that the DR chains do 
pair with the IE chains, thus contributing to any observed 
response.  IL-2 release,  as determined by stimulation of an 
IL-2-dependent T cell line CTLL-2, and adhesion, as deter- 
mined visually by clustering, were used to determine the ability 
of the T  cells to recognize both allogeneic and xenogeneic 
MHC class II molecules. Minimal levels of IL-2 release and 
adhesion were observed in response to either syngeneic, ir- 
radiated BALB/c splenocytes, or the untransfected BALB/c- 
derived A20.J cells (Fig.  3). In contrast, a strong response, 
in terms of IL-2 release and adhesion, was seen towards al- 
logeneic B6 splenocytes and the Aoe/A/3 A20.J transfectants. 
As expected, only a weak but positive xenogeneic response 
was  observed towards  the DILc~/DR/3  transfectant.  It  is 
striking that both adhesion and T cell function responses to 
AoJA/31:DRB2 were substantially reduced, but not ablated, 
as a result of the inclusion of a foreign/32 domain in IA. 
This inferred the presence of a species barrier in the interac- 
tion between mouse CD4 and the/32 domain of human class 
II molecules. However, the fact that some response still re- 
mains suggests that several interaction sites between these 
molecules may exist and that some, but not all, are species 
specific. It is interesting that the presence of an IAb2 domain 
in DR (DRc~/DRBl:A/32) failed to restore the defect. There 
are three possible explanations. First, binding has only been 
partially ablated because of the involvement of the/31 do- 
main; second, two CD4 molecules bind to the same class 
II molecules, and binding of one of these to the ot chain is 
unaffected; or third, CD4 serves a novel, and as yet undescribed 
function that does not require CD4 binding to class II. In 
support of the latter, we have recently shown that CD4 in- 
teracts with the TCR and may help to maintain the fidelity 
of T cell specificity (Vignali, D., et al., manuscript submitted 
for publication). Alternatively, the residual response seen could 
be due to a small percentage of CD4 independent T  cells 
present in the heterogeneous pool of alloreactive cells. 
The second experimental system employed the use of a panel 
of murine IAc~/3b-restricted T  cell hybridomas specific for 
the peptide 46--61 of HEL. Initially, eight individually cloned 
hybridomas with the same specificity and restriction element 
were assayed for their ability to recognize both the whole 
protein HEL and the poptide 46-61 presented by either AcffA/3 
or Aot/A/31:DR432 A20.J transfectants. Fig. 4 shows repre- 
sentative data of the response of two of those hybridomas, 
A167 and A481,  to HEL 46-61.  All the hybridomas tested 
clearly  responded  better  to  the  Aot/A/3  than  the  Acff 
A/31:DR/32 transfectants.  Similar results were obtained when 
either responses to the whole HEL molecule were analyzed, 
or L cell transfectants were used as presenters (data not shown). 
One hybridoma, A167, was selected for further study. 
If the results above truly indicate that CD4 binds to the 
/32 domain of class II molecules in a species-specific manner, 
one should be able to make two predictions. First, CD4 loss 
variants of A167 should respond comparably to AcffA/3 and 
Aol/A/31:lDR~2; and second, reexpression of CD4 by these 
hybridomas by transfection should restore the parental pheno- 
type. Both predictions were found to be correct. 
CD4 loss variants of A167 were isolated by FACS  |  One 
clone, A167.N, was chosen for further study because of its 
possessing comparable levels of TCR, CD3, CD2, and LFA-1 
expression to A167,  and comparable responses to immobi- 
lized anti-TCR and -CD3  (Vignali, D.,  et al.,  manuscript 
submitted for publication). Although, not surprisingly, A167 
responded far better than A167.N,  detectable levels of IL-2 
release were still  observed at 3-/~M peptide (Fig.  5 A).  In 
contrast to A167, which reacted noticeably better to Aot/A/3 
than did Aoe/A/31:DR,82,  the response to these transfectants 
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Figure 5.  (.4)  Response  ofA167, A167.N 
(CD4  loss variant  of  A167),  and 
A167.N.mCD4 (A167.N transfected  with 
mouse CD4) to HEL 46-61 presented  by 
Acc/A/~  and Aot/ABI:DRB2. (B) Response 
of A167.N, A167.N.mCD4 and A167. 
N.hCD4 (A167.N transfected  with human 
CD4) to HEL 46-61 presented  by Ao~/A~ 
and AcffA/~I:DRB2. Data presented are 
representative  of five experiments  and are 
expressed  as the mean  of triplets. Standard 
deviations  were  typically  below 10% of  the 
total The experiments  in B were  performed 
with a highly  purified  batch  of  HEL 46-61 
peptide resulting in lower concentrations 
being required for stimulation of the hy- 
bridomas compared with A. 
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port the notion that  the exon shuffling procedure had not 
altered the ability of the TCR to recognize its peptide/MHC 
combination. When A167.N was transfected with the mouse 
CD4 cDNA under the control of a human/$ actin promoter, 
several clones were isolated that had levels of CD4 comparable 
to A167 (data not shown). As expected, reexpression of CD4 
by the A167.N.mCD4 transfected hybridomas restored the 
original parental phenotype exhibited by A167 (Fig.  5 A). 
These data clearly demonstrate that the reduced responsive- 
ness to Aot/A/$1:DtL82 is due to inefficient binding of CD4 
to MHC class II molecules. It is interesting that the response 
of A167 to Aot/A/$1:DRB2 was not completely reduced down 
to the level of A167.N. This may suggest either that  CD4 
binds to another part of the IA molecule other than the/$2 
domain,  or that  CD4 is performing  another  function that 
does not  require  a high  degree of binding  to MHC. 
The final question addressed was whether the transfection 
of the CD4 loss variant  A167.N  with  human  CD4 could 
restore reactivity to Aot,A/$1:DtL82.  Both A167.N.mCD4 
and A167.N.hCD4  expressed comparable levels of CD4 as 
determined by flow cytometry. In contrast  to the observa- 
tions with A167.N.mCD4,  the response to A167.N.hCD4 
of the two transfectants was identical not only to each other 
but also to the response to A167.N.mCD4 of Aot/A/$1:DI~82 
(Fig. 5 B). These data may suggest that hCD4 cannot fully 
replace mCD4, and that a similar barrier exists between hCD4 
and mouse class II. However, this conclusion would contradict 
the observations of yon Hoegen et al., (16) who found that 
mouse and human CD4 were comparable in their ability to 
enhance T cell responses in their system. Three potential differ- 
ences may account for these discrepancies: first, the hybrid- 
omas used in the present study are ,05 times more sensitive; 
second, our studies were primarily based on observations using 
peptides rather than whole proteins; and third, all our clones 
were tested for their comparable ability to produce II~2 in 
response to immobilized anti-TCK and -CD3, controls which 
were not indicated in their studies. Alternatively, the reduced 
responses could be due to lower levels of hCD4 compared 
with mCD4 that could not be discerned by FACS  |  analysis. 
If this conclusion were correct, our data would imply that 
hCD4  can bind  to both  mouse  and  human  class  II,  cor- 
roborating  the conclusions of von Hoegen et  al.  (16). 
One prominent feature of this present study was that the 
reduction in response of both mouse and human  CD4 + T 
cell hybridomas to the exon-shuffled molecules was only one 
third of that seen with the CD4-  hybridomas. Two possible 
explanations present themselves:  (a) binding is not completely 
abrogated because CD4 also binds to other class II domains 
and/or the species barrier is partial;  or (b) binding is com- 
pletely ablated and the partial  response observed is due to 
the existence of a novel function for CD4. Evidence for both 
of these possibilities exists. 
Evidence forthe former notion has come from several studies 
that  have speculated that  CD4 may bind to either  the or1 
or/$1 domains on class II (13-15). Furthermore,  two groups 
have shown that between three and four contact sites for class 
II exist spanning over two or three CD4 domains, implying 
the presence of a large contact area (10--12). However, these 
studies have also shown that the removal of  just one of these 
was suffident to completely abrogate binding and functional 
activity. This would tend to suggest that even if there were 
more than one domain involved in binding,  the removal of 
just one binding residue would result in no significant binding 
between CD4 and class II. Alternatively, binding may not 
be completely lost if CD4 bound to both the c~ and/$ chains. 
Evidence that  two CD4 molecules may associate with  the 
same TCR/CD3 complex has come from the studies of An- 
derson et al. (34), raising the possibility that CD4 may bind 
to both the c~ and/$ chains of class II, This scenario could 
explain differences between our findings and those of others 
(14,  15, 17) that CD4 binds to the/$ chain, and the sugges- 
tions of Zhou et al., (13) that CD4 may bind to the or1 do- 
main.  It is possible that when a foreign/$2 domain is intro- 
duced, one CD4 molecule can no longer bind to the/$ chain, 
and binding of the other to the c~ chain is unaffected. This 
may  explain  why  the  responses  of  A167.N.mCD4  to 
AoUA/$1:DR~2,  and  A167.N.hCD4  to both Aot/A/$ and 
Aot/A/$1:DR/~2 were all identical, yet were all stronger than 
the response seen  with  A167.N. 
The  second possible explanation  which may,  at least in 
part,  explain why some of these responses are not reduced 
down to the level of the CD4 loss variant, comes from data 
we have recently obtained that suggests that CD4 may help 
to maintain the fidelity of the TCK (Vignali,  D., et al., manu- 
script submitted for publication).  These studies imply that 
the presence of CD4 can be important in allowing the TCK 
to effectively recognize its class  II/peptide ligand.  Conse- 
quently, in the absence of CD4, the TCR would recognize 
the class  II/peptide complex less effectively. 
In conclusion,  our experiments imply the existence of a 
species barrier in the interaction between CD4 and the class 
II/$2 domain.  Furthermore,  the evidence presented here is 
consistent with the suggestions of others (10-15) that CD4 
may also bind to the class IIc~ and/or/$1  domains.  In addi- 
tion, the data imply that the species barrier may only be par- 
tial. However, it is also possible that the apparent species barrier 
is indirect, with various portions of the class II molecule in- 
terfering with  the binding of murine  CD4 to a conserved 
site that  itself is not  species  specific. 
In an attempt  to produce a model for CD4/MHC  class 
II interaction,  two observations are worthy of note.  First, 
Anderson et al., (34) have shown that  10% of surface CD4 
is internalized after CD3 modulation, and only 5% of CD3 
is internalized  after CD4 modulation, implying that two CD4 
molecules may associate with the same TCR/CD3 complex. 
Second, a number of studies have shown that several residues 
on opposing sides of the CD4 molecule are involved in binding 
class II molecules (10-12). On the basis of these observations 
and the data presented here, it is tempting to speculate that 
two CD4 molecules may bind to the same CD3/TCK com- 
plex, not as a dimer, but as separate molecules, with one side 
of one CD4 molecule binding to the c~ chain, and the other 
side of the second CD4 molecule binding  to the/$  chain. 
930  CD4 Binds to the B2 Domain of MHC Class lI Molecules It is hoped that the data presented here and this model will 
assist in the elucidation of the exact contact residues between 
CD4 and MHC class II molecules. Furthermore, the obser- 
vation of a species barrier in the interaction between CD4 
and DR. molecules is relevant to the establishment of models 
for autoimmune diseases in human class II transgenic mice. 
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